Alendronate Can Improve Bone Alterations in Experimental Diabetes by Preventing Antiosteogenic, Antichondrogenic, and Proadipocytic Effects of AGEs on Bone Marrow Progenitor Cells

Figure 2

Effect of AGEs and/or alendronate on BMPC adipocytic differentiation. BMPC were obtained from nondiabetic untreated animals and cultured for 10 days in an adipogenic medium with 200 mg/mL of either control BSA or AGE-BSA, in the presence or absence of 10⁻⁸ M alendronate. Contrast-phase images show intracellular lipid droplets of the monolayer exposed to control BSA (a) or AGEs-BSA (b) (Obj. 40x). Intracellular triglyceride accumulation (TG) (c), lipase enzymatic activity (d), and expression of PPAR-γ by Western blot (e) were evaluated as markers of adipogenic differentiation. Results are expressed as the mean ± SEM. versus control BSA; versus AGEs-BSA.

(a)

(b)

(c)

(d)

(e)